All Stories

  1. Genomic and transcriptomic characterization of the mitochondrial-rich oncocytic phenotype on a thyroid carcinoma background
  2. Dynamin-Related Protein 1 at the Crossroads of Cancer
  3. Etiopathogenesis of oncocytomas
  4. Telomerase and N-Cadherin in Adrenocortical Tumors
  5. An overview on the role of autophagy in cancer therapy
  6. The prognostic impact of TERT promoter mutations in glioblastomas is modified by the rs2853669 single nucleotide polymorphism
  7. Thyroid and Parathyroid Glands
  8. STAT3:FOXM1 and MCT1 drive uterine cervix carcinoma fitness to a lactate-rich microenvironment
  9. A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapy
  10. Overexpression of pyruvate dehydrogenase kinase supports dichloroacetate as a candidate for cutaneous melanoma therapy
  11. Mitochondrial Dynamics Protein Drp1 Is Overexpressed in Oncocytic Thyroid Tumors and Regulates Cancer Cell Migration
  12. Loss of Mitochondrial SDHB Expression: What is its Role in Diffuse Thyroid Lipomatosis?
  13. OXPHOS dysfunction regulates integrin- 1 modifications and enhances cell motility and migration
  14. Telomerase promoter mutations in cancer: an emerging molecular biomarker?
  15. TERT Promoter Mutations Are a Major Indicator of Poor Outcome in Differentiated Thyroid Carcinomas
  16. Mitochondria dynamism: of shape, transport and cell migration
  17. Oncocytic Lesions of the Thyroid, Kidney, Salivary Glands, Adrenal Cortex, and Parathyroid Glands
  18. Mitochondrial D310 D-Loop instability and histological subtypes in radiation-induced cutaneous basal cell carcinomas
  19. A founder SDHB mutation in Portuguese paraganglioma patients
  20. Frequency of TERT promoter mutations in human cancers
  21. Molecular alterations and expression of succinate dehydrogenase complex in wild-type KIT/PDGFRA/BRAF gastrointestinal stromal tumors
  22. STAT3 negatively regulates thyroid tumorigenesis
  23. RET/PTCrearrangement is prevalent in follicular Hürthle cell carcinomas
  24. The biology and the genetics of Hurthle cell tumors of the thyroid
  25. Absence of theBRAFand theGRIM-19Mutations in Oncocytic (Hürthle Cell) Solid Cell Nests of the Thyroid
  26. Somatic mitochondrial DNA mutations in cancer escape purifying selection and high pathogenicity mutations lead to the oncocytic phenotype: pathogenicity analysis of reported somatic mtDNA mutations in tumors
  27. A novel germline SDHB mutation in a gastrointestinal stromal tumor patient without bona fide features of the Carney–Stratakis dyad
  28. Genetic Alterations in Poorly Differentiated and Undifferentiated Thyroid Carcinomas
  29. GRIM-19 function in cancer development
  30. Orthovanadate-induced cell death in RET/PTC1-harboring cancer cells involves the activation of caspases and altered signaling through PI3K/Akt/mTOR
  31. Synergistic growth inhibition of cancer cells harboring the RET/PTC1 oncogene by staurosporine and rotenone involves enhanced cell death
  32. Involvement of p53 in cell death following cell cycle arrest and mitotic catastrophe induced by rotenone
  33. An assessment of the clonality of the components of canine mixed mammary tumours by mitochondrial DNA analysis
  34. The Diversity Present in 5140 Human Mitochondrial Genomes
  35. Helicobacter pylori Infection Induces Genetic Instability of Nuclear and Mitochondrial DNA in Gastric Cells
  36. Mitochondria and cancer
  37. How molecular pathology is changing and will change the therapeutics of patients with follicular cell-derived thyroid cancer
  38. Mitochondria and Oncocytomas
  39. Optimization of methods to assess mitochondrial DNA in archival paraffin-embedded tissues from mammary canine tumors
  40. Intragenic Mutations in Thyroid Cancer
  41. GRIM-19 mutations are not associated with Crohnʼs disease
  42. GRIM-19 in Health and Disease
  43. High Frequency of Germline Succinate Dehydrogenase Mutations in Sporadic Cervical Paragangliomas in Northern Spain: Mitochondrial Succinate Dehydrogenase Structure-Function Relationships and Clinical-Pathological Correlations
  44. Molecular and Genotypic Characterization of Human Thyroid Follicular Cell Carcinoma–Derived Cell Lines
  45. Molecular genetics of papillary thyroid carcinoma: great expectations...
  46. Warthin's tumour
  47. Reply to: Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas
  48. Mitochondrial D-Loop instability in thyroid tumours is not a marker of malignancy
  49. Molecular pathology of well-differentiated thyroid carcinomas
  50. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients’ age but not with tumour aggressiveness
  51. Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hürthle cell) tumours of the thyroid
  52. Hürthle (Oncocytic) Cell Tumors of Thyroid: Etiopathogenesis, Diagnosis and Clinical Significance
  53. BRAFMutations Are Not a Major Event in Post-Chernobyl Childhood Thyroid Carcinomas
  54. Core I gene is overexpressed in Hürthle and non-Hürthle cell microfollicular adenomas and follicular carcinomas of the thyroid
  55. BRAF mutations are associated with some histological types of papillary thyroid carcinoma
  56. Germline Succinate Dehydrogenase Subunit D Mutation Segregating with Familial Non-RET C Cell Hyperplasia
  57. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC
  58. Letter to the editor
  59. Mucoepidermoid carcinoma of the thyroid: a tumour histotype characterised by P-cadherin neoexpression and marked abnormalities of E-cadherin/catenins complex
  60. Microsatellite instability, mitochondrial DNA large deletions, and mitochondrial DNA mutations in gastric carcinoma
  61. Abnormalities of the E-cadherin/catenin adhesion complex in classical papillary thyroid carcinoma and in its diffuse sclerosing variant
  62. Mitochondrial DNA ‘common’ deletion in Hürthle cell lesions of the thyroid
  63. Mitochondrial DNA alteration in gastric cancer
  64. A new PKLR gene mutation in the R-type promoter region affects the gene transcription causing pyruvate kinase deficiency
  65. Hürthle cell tumours of the thyroid. A review with emphasis on mitochondrial abnormalities with clinical relevance
  66. Comments on: Mutations in Mitochondrial Control Region DNA in Gastric Tumours of Japanese Patients, Tamura, et al. Eur J Cancer 1999, 35, 316–319
  67. The Common Deletion of Mitochondrial DNA is Found in Goiters and Thyroid Tumors with and Without Oxyphil Cell Change